Reevaluation and identification of the best immunohistochemical panel (pVHL, maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 6, 2012, Pages 601-609

  Liu, Haiyan ^a   Shi, Jianhui ^a   Anandan, Vasuki ^a   Wang, Hanlin L ^c   Diehl, David ^a   Blansfield, Joseph ^a   Gerhard, Glenn ^b   Lin, Fan ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b WEIS CENTER FOR RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; NEEDLE BIOPSY; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

BIOPSY, FINE-NEEDLE; CARCINOMA, PANCREATIC DUCTAL; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREAS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864245558     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0326-OA     Document Type: Article

References (53)

1. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32(1):78-91.
2. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2008;129(1):81-88. (Pubitemid 352038597)
3. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166(1):81-92. (Pubitemid 40051662)
4. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, et al. Molecular alterations in pancreatic carcinoma: expression profiling shows thatdysregulated expression of S100 genes is highly prevalent. J Pathol. 2003;201(1):63-74. (Pubitemid 37121204)
5. Sato N, Fukushima N, Matsubayashi H, Goggins M. Identification ofmaspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 2004;23(8):1531-1538. (Pubitemid 38406515)
6. Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von HippelLindau gene product (pVHL) in human tissues and tumors: a diagnostic markerfor metastatic renal cell carcinoma and clear cell carcinoma ofthe ovary and uterus. Am J Clin Pathol. 2008;129:592-605. (Pubitemid 352029279)
7. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von HippelLindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol. 2010;41(9):1210-1219.
8. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29(2):188-195. (Pubitemid 40170636)
9. Zhao H, Mandich D, Cartun RW, Ligato S. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol. 2007;35(11):700-704. (Pubitemid 350035041)
10. Cao D, Zhang Q, Wu LS, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol. 2007;20(5):570-578. (Pubitemid 46631999)
11. Kashima K, Ohike N, Mukai S, Sato M, Takahashi M, Morohoshi T. Expression of the tumor suppressor gene maspin and its significance in intraductal papillary mucinous neoplasms of the pancreas. Hepatobiliary Pancreat Dis Int. 2008;7(1):86-90. (Pubitemid 351247063)
12. Ohike N, Maass N, Mundhenke C, et al. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett. 2003;199(2):193-200. (Pubitemid 37297712)
13. Agarwal B, Ludwig OJ, Collins BT, Cortese C. Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol. 2008;6(12):1425-1431.
14. McCarthy DM, Maitra A, Argani P, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol. 2003;11(3):238-243. (Pubitemid 37082060)
15. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27(11):1418-1428. (Pubitemid 37315193)
16. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124(6):838-845. (Pubitemid 41740183)
17. Frierson HF Jr, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34(6):605-609. (Pubitemid 36750373)
18. Wente MN, Jain A, Kono E, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005;31(2):119-125. (Pubitemid 41077139)
19. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001;61(11):4320-4324. (Pubitemid 32685751)
20. Karanjawala ZE, Illei PB, Ashfaq R, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol. 2008;32(2):188-196. (Pubitemid 351172132)
21. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186.
22. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohisto-chemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27(3):303-310. (Pubitemid 36245795)
23. Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF Jr. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol. 2003;16(9): 913-919. (Pubitemid 37152021)
24. De Lott LB, Morrison C, Suster S, Cohn DE, Frankel WL. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med. 2005;129(9):1100-1105. (Pubitemid 41242420)
25. Goldstein NS, Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas: percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol. 2001; 115(5):695-702. (Pubitemid 33051536)
26. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol. 2005;29(3):381-389. (Pubitemid 40321975)
27. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13(9):962-972.
28. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 2005; 29(3):359-367. (Pubitemid 40321972)
29. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohisto-chemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33(12):1175-1181. (Pubitemid 36020066)
30. Nagata K, Horinouchi M, Saitou M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg. 2007; 14(3):243-254. (Pubitemid 46863913)
31. Bhardwaj A, Marsh WL Jr, Nash JW, Barbacioru CC, Jones S, Frankel WL. Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray-based study. Arch Pathol Lab Med. 2007;131(4):556-562. (Pubitemid 46564427)
32. Apple SK, Hecht JR, Lewin DN, Jahromi SA, Grody WW, Nieberg RK. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol. 1999;30(2):123-129. (Pubitemid 29086941)
33. DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol. 1994;101(6):684-688. (Pubitemid 24169297)
34. Swierczynski SL, Maitra A, Abraham SC, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35(3):357-366. (Pubitemid 38339611)
35. Jhala N, Jhala D, Vickers SM, et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol. 2006;126(4):572-579.
36. Cao D, Maitra A, Saavedra JA, Klimstra DS, Adsay NV, Hruban RH. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol. 2005;18(6):752-761. (Pubitemid 40780508)
37. Chhieng DC, Benson E, Eltoum I, et al. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. Cancer. 2003; 99(6):365-371. (Pubitemid 38017536)
38. Giorgadze TA, Peterman H, Baloch ZW, et al. Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas: an immunohisto-chemical study with surgical pathology correlation. Cancer. 2006;108(3):186-197.
39. Yamaguchi H, Inoue T, Eguchi T, et al. Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade. Mod Pathol. 2007;20(5):552-561. (Pubitemid 46631991)
40. van Heek T, Rader AE, Offerhaus GJ, et al. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol. 2002;117(5):755-765. (Pubitemid 34457011)
41. Lin F, Shi J, Wang HL, Liu J. Reevaluation and identification of the best immunohistochemical panel for adenocarcinoma of the pancreas [abstract 1613]. Mod Pathol. 2010;23(suppl 1s):363A.
42. Anandan V, Shi J, Liu H, Meschter S, Lin F. Identification of an effective antibody panel in the diagnosis of pancreatic ductal adenocarcinoma on fine needle aspiration biopsy specimens [abstract 381]. Mod Pathol. 2010;23 (suppl 1s):87A.
43. Kosarac O, Takei H, Zhai QJ, Schwartz MR, Mody DR. S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology. Acta Cytol. 2011;55(2): 142-148.
44. Nakata K, Nagai E, Ohuchida K, et al. S100P is a novel marker to identify intraductal papillary mucinous neoplasms. Hum Pathol. 2010;41(6):824-831.
45. Wachter DL, Schlabrakowski A, Hoegel J, Kristiansen G, Hartmann A, Riener MO. Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2011; 35(6):873-877.
46. Dim DC, Jiang F, Qiu Q, et al. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration [published online ahead of print April 28, 2011]. Diagn Cytopathol. doi:10.1002/dc.21684.
47. Lin F, Zhang PL, Yang XJ, et al. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol. 2007;31(3):371-381. (Pubitemid 46673110)
48. Liu H, Shi J, Wilkerson M, et al. Immunohistochemical detection of p16INKa in liquid-based cytology specimens on cell block sections. Cancer. 2007;111 (2):74-82. (Pubitemid 46648405)
49. Lin F, Shi J, Wang HL, Liu H. Diagnostic utility of von Hipple-Lindau gene product (pVHL), maspin, KOC, and S100Pin adenocarcinoma of the gallbladder [abstract 1612]. Mod Pathol. 2010;23(suppl 1s):363A.
50. Lin F, Shi J, Liu H, Prichard JW, Wang HL. CK17, MUC5AC, pVHL, and S100P are the effective antibody panel in differentiating intrahepatic cholangiocarcinoma from pancreatic adenocarcinoma [abstract 1556]. Mod Pathol. 2011;24(suppl 1s): 367A.
51. Lin F, Shi J, Wang HL, Wilkerson M, Liu H. Utility of pVHL, maspin, S100P and IMP3 in diagnosis of carcinomas from various organs adenocarcinoma [abstract 1557]. Mod Pathol. 2011;24(suppl 1s):367A.
52. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol. 2000;156(1):37-43. (Pubitemid 30644436)
53. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002;21(4):391-400.